2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Carcinoma, Hepatocellular
3
Prostatic Neoplasms
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Atherosclerosis
1
Interventions
Exercise
4
Cholecalciferol
4
Aspirin
4
Nutrition Assessment
3
Gonadotropin-Releasing Hormone
3
Blood Pressure
3
Atorvastatin
3
palbociclib
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
acalabrutinib
2
Vitamin E
2
Vitamin D
2
Social Determinants of Health
2
Rosuvastatin Calcium
2
Methods
2
Metformin
2
Geritol
2
Fish Oils
2
Fatty Acids, Omega-3
2
Ethanol
2
Electrocardiography
2
Educational Status
2
Echocardiography
2
Diet, Mediterranean
2
Blood Specimen Collection
2
Antineoplastic Agents
2
Absorptiometry, Photon
2
zanubrutinib
1
xinmailong
1
sofosbuvir-velpatasvir drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiovascular Diseases
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03127631
2025-01-31
RADICALPC
McMaster University
Phase NA
Recruiting
6,000 enrolled